Werewolf Therapeutics, Inc. HOWL NASDAQ

Werewolf Therapeutics, Inc. (HOWL) reported total assets of $69.4M and total liabilities of $44.59M for fiscal year 2025, resulting in total equity of $24.81M.

The company held $57.95M in cash and short-term investments. Total debt stood at $9.44M, with net debt of $-48.52M. The Debt-to-Equity (D/E) ratio was 0.38 (conservative).

Current ratio is 1.62, indicating strong short-term liquidity. Interest coverage is -11.5x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (0/100) — Total assets $69.4M and equity $24.81M support the company's competitive scale
• VALUE (60/100) — Debt-to-Equity 0.38 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 37/100 with 2/7 criteria passed.

CELC

Celcuity Inc.

$123.47

+2.17%

EWTX

Edgewise Therapeutics, Inc.

$33.70

+1.63%

STOK

Stoke Therapeutics, Inc.

$35.54

-0.89%

GLUE

Monte Rosa Therapeutics, Inc.

$18.23

+4.17%

CGEM

Cullinan Oncology, Inc.

$14.95

+4.18%

DSGN

Design Therapeutics, Inc.

$12.75

+0.87%

IKNA

Ikena Oncology, Inc.

$17.16

+1,152.55%

ELYM

Eliem Therapeutics, Inc.

$5.11

-0.97%